Clinical Trial Update: Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing lesion-to-lesion imaging using 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT for evaluating metastatic neuroendocrine tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 18F-DOPA (fluorodopa)
• 18F-FDG (fluorodeoxyglucose F-18)
• 68Ga-HA-DOTATATE (Ga-68 DOTATATE radiotracer)

Snippet

Sponsor: University of Alberta | Conditions: Neuroendocrine Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING